Paul Cheng
Research Subjects
Paul Cheng has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Christina To
Kite, a Gilead Company, Santa Monica, California
40 shared publications - Jason R. Westin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
40 shared publications - Saran Vardhanabhuti
Kite, a Gilead Company, Santa Monica, California
40 shared publications - Simone Filosto
Kite, a Gilead Company, Santa Monica, California
40 shared publications - Aaron P. Rapoport
Division of Hematology/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
33 shared publications - Anna Sureda
Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
33 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Overall survival (interim) and progression-free survival in patients ≥70 years
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Overall survival (interim) and progression-free survival in patients ≥70 years
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Event-free survival per central review and objective response rate in patients ≥70 years
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Event-free survival per central review and objective response rate in patients ≥70 years
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Sensitivity analysis of interim overall survival in patients ≥65 years
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Sensitivity analysis of interim overall survival in patients ≥65 years
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Tabulated data supporting ZUMA-7 elderly analysisSupplementary Table S1. Patient-reported outcomes instrumentsSupplementary Table S2. Axi-cel delivery and administration timeSupplementary Table S3. Summary of efficacy and safety outcomes in patients ≥65 years versus all patients in ZUMA-7Supplementary Table S4. Serious adverse events in at least 3 patients in patients ≥65 yearsSupplementary Table S5. Summary of cytopenias present on or after 90 days from initiation of definitive therapy on protocol in patients ≥65 yearsSupplementary Table S6. Deaths in axi-cel and SOC arms for patients ≥65 years (safety analysis set)Supplementary Table S7. Summary of serum analytes in patients <65 years versus ≥65 years in the axi-cel arm (N = 170)Supplementary Table S8. Most common adverse events, cytokine release syndrome, and neurologic events in patients ≥70 yearsSupplementary Table S9. Deaths in axi-cel and SOC arms for patients ≥70 years Supplementary Table S10. Baseline characteristics for quality-of-life analysis in patients ≥65 yearsSupplementary Table S11. Mixed model with repeated measures estimated difference in change from baseline forprespecified patient-reported outcomes measures (quality-of-life analysis set) in patients ≥65 years
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Tabulated data supporting ZUMA-7 elderly analysisSupplementary Table S1. Patient-reported outcomes instrumentsSupplementary Table S2. Axi-cel delivery and administration timeSupplementary Table S3. Summary of efficacy and safety outcomes in patients ≥65 years versus all patients in ZUMA-7Supplementary Table S4. Serious adverse events in at least 3 patients in patients ≥65 yearsSupplementary Table S5. Summary of cytopenias present on or after 90 days from initiation of definitive therapy on protocol in patients ≥65 yearsSupplementary Table S6. Deaths in axi-cel and SOC arms for patients ≥65 years (safety analysis set)Supplementary Table S7. Summary of serum analytes in patients <65 years versus ≥65 years in the axi-cel arm (N = 170)Supplementary Table S8. Most common adverse events, cytokine release syndrome, and neurologic events in patients ≥70 yearsSupplementary Table S9. Deaths in axi-cel and SOC arms for patients ≥70 years Supplementary Table S10. Baseline characteristics for quality-of-life analysis in patients ≥65 yearsSupplementary Table S11. Mixed model with repeated measures estimated difference in change from baseline forprespecified patient-reported outcomes measures (quality-of-life analysis set) in patients ≥65 years
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
CAR T-cell levels in patients ≥65 years
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
CAR T-cell levels in patients ≥65 years
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Mixed model with repeated measures for change from baseline for prespecified patient-reported outcomes endpoints in patients ≥65 years
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Mixed model with repeated measures for change from baseline for prespecified patient-reported outcomes endpoints in patients ≥65 years
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Purpose:Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.Patients and Methods:Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2–3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).Results:Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years.Conclusions:Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Purpose:Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.Patients and Methods:Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2–3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).Results:Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years.Conclusions:Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.